Positives

• In the 48-week phase 2 trial, patients lost an average of 24.2% of body weight at the 12 mg dose, with 26% losing more than 30% NEJM.
  
  
• Many reviewers who had stalled on Wegovy or Mounjaro described their weight resuming a steady drop and a complete absence of food noise after switching to retatrutide Diabetes.co.uk.
  
  

Negatives

• Roughly 60% of trial participants on the 12 mg dose experienced nausea during dose escalation, with skin dysesthesia (a burning, sunburn-like sensation) reported by about 21% NEJM.
  
  
• Patients reported a dose-dependent rise in heart rate and described feeling wiped out enough at higher doses to need afternoon naps PMC.
  
  

Hurdles & Side Effects

• Because retatrutide is still investigational and unapproved, patients sourcing it through gray-market peptide vendors face counterfeit risk and no clinician oversight Diabetes.co.uk.
  
  
• Patients who skipped the slow titration and started above 2 mg reported debilitating GI symptoms and early discontinuation that careful dose-stepping likely would have prevented PMC.